Aglaia Oncology Funds
Mark Krul is the Chief Scientific Officer at Oncode Accelerator and serves as a Board Member at MIMETAS, Cristal Therapeutics, Macrophage Pharma Ltd., and Inthera Bioscience AG. Mark is the Founder and Director of Aglaia Oncology Fund II. With a Ph.D. in Medical Biology from Utrecht University, Mark has a wealth of experience in drug development and research management in the field of oncology.
This person is not in any teams
Aglaia Oncology Funds
Aglaia is an investment fund fully focused on the fight against cancer and the development of improved anti-cancer drugs in particular. Aglaia has a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment. For more information, please visit www.aglaia-oncology.com